Display options
Cite
Wen J, Li HZ, Ji ZG, et al. Human urothelial carcinoma cell response to Sunitinib malate therapy in vitro. Cancer Cell Int. 2015;15:26doi: 10.1186/s12935-015-0179-z.
Wen, J., Li, H. Z., Ji, Z. G., Jin, J., & Reilly, B. (2015). Human urothelial carcinoma cell response to Sunitinib malate therapy in vitro. Cancer cell international, 1526. https://doi.org/10.1186/s12935-015-0179-z
Wen, Jin, et al. "Human urothelial carcinoma cell response to Sunitinib malate therapy in vitro." Cancer cell international vol. 15 (2015): 26. doi: https://doi.org/10.1186/s12935-015-0179-z
Wen J, Li HZ, Ji ZG, Jin J, Reilly B. Human urothelial carcinoma cell response to Sunitinib malate therapy in vitro. Cancer Cell Int. 2015 Feb 28;15:26. doi: 10.1186/s12935-015-0179-z. eCollection 2015. PMID: 25745360; PMCID: PMC4350454.
Copy Download .nbib Format: NLM
Share it on

Cancer Cell Int. 2015 Feb 28;15:26. doi: 10.1186/s12935-015-0179-z. eCollection 2015.

Human urothelial carcinoma cell response to Sunitinib malate therapy in vitro.

Cancer cell international

Jin Wen, Han-Zhong Li, Zhi-Gang Ji, Jing Jin, Reilly

Affiliations

  1. Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Shuai Fu Yuan 1, Wang Fu Jin Street, Beijing, 100730 China.
  2. Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

PMID: 25745360 PMCID: PMC4350454 DOI: 10.1186/s12935-015-0179-z

Abstract

OBJECTIVES: Bladder transitional cell carcinoma (TCC) is one of the most common solid malignancies in China. This study examined the antitumor effect and underlying mechanism of action of sunitinib malate in human bladder TCC in vitro.

METHODS: Bladder TCC cell lines 5637 and BIU87 were maintained in 1640 medium and T24 cell lines in DMEM/F12 medium. All 3 cell lines were then exposed to graded concentrations (0.625-20 μmol/L) of sunitinib malate, sorafenib and cisplatin for 24-96 hours to determine the sensitivities to each drug. Cell viability was measured by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium] assay, and apoptosis was analyzed by flow cytometry. Cell apoptotic morphology was observed by a fluorescence microscope after DAPI (4',6-diamidino-2-phenylindole) staining. Protein concentrations were measured by western blot.

RESULTS: Sunitinib malate showed a concentration-dependent inhibitory effect on the 5637, T24 and BIU87 cell lines with IC50's of 1.74 μmol/L, 4.22 μmol/L, and 3.65 μmol/L, respectively. Cisplatin also exhibited good antitumor activity, but whereas sorafenib suppressed proliferation of the cells at concentrations of 10 μmol/L or higher, there was practically no response at lower concentrations. Sunitinib malate treatment resulted in an accumulation of cells in the sub-G1 phase, especially with the T24 and BIU87 cell lines, which induced apoptosis of the cells.

CONCLUSIONS: Sunitinib malate exerted marked inhibitory activity against bladder cancer cells. The cell growth inhibitory effect of the drug was related to induction of apoptosis. These results suggest that clinical application of sunitinib-based therapy for advanced bladder cancer is possible.

Keywords: Bladder cancer; Cisplatin; Proliferation; Sorafenib; Sunitinib

References

  1. Urol Int. 2008;81(1):72-6 - PubMed
  2. Oncologist. 2007 Jan;12 (1):107-13 - PubMed
  3. J Clin Oncol. 2008 Apr 10;26(11):1810-6 - PubMed
  4. J Clin Oncol. 2007 Oct 20;25(30):4793-9 - PubMed
  5. JAMA. 2006 Jun 7;295(21):2516-24 - PubMed
  6. Korean J Urol. 2011 Jan;52(1):55-63 - PubMed
  7. Biochem Biophys Res Commun. 2007 May 4;356(2):323-8 - PubMed
  8. J Urol. 1998 Nov;160(5):1932 - PubMed
  9. Pathol Oncol Res. 2009 Jun;15(2):193-201 - PubMed
  10. J Clin Oncol. 2008 Feb 1;26(4):650-6 - PubMed
  11. Prog Urol. 2001 Jun;11(3):417-27 - PubMed
  12. Med Hypotheses. 2007;69(4):892-5 - PubMed

Publication Types